Mesoporous silica formulation strategies for drug dissolution enhancement: a review

Bibliography

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

• Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–249.
   PubMed Web of Science ®Google Scholar
• van Hoogevest P, Liu X, Fahr A. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opin Drug Deliv. 2011;8(11):1481–1500.
   PubMed Web of Science ®Google Scholar
• Monkhouse DC, Lach JL. Use of adsorbents in enhancement of drug dissolution. I. J Pharm Sci. 1972;61(9):1430–1435.
   Web of Science ®Google Scholar
• Unger K, Rupprecht H, Valentin B, et al. The use of porous and surface modified silicas as drug delivery and stabilizing agents. Drug Dev Ind Pharm. 1983;9(1–2):69–91.
   Web of Science ®Google Scholar
• Vallet-Regi M, Ramila A, Del Real R, et al. A new property of MCM-41: drug delivery system. Chem Mater. 2001;13(2):308–311.
   Web of Science ®Google Scholar

**First report on the use of mesoporous silica for controlled drug delivery.

• Van Speybroeck M, Barillaro V, Thi TD, et al. Ordered mesoporous silica material SBA‐15: a broad‐spectrum formulation platform for poorly soluble drugs. J Pharm Sci. 2009;98(8):2648–2658.
   PubMed Web of Science ®Google Scholar
• Mellaerts R, Aerts CA, Humbeeck JV, et al. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem Commun. 2007;13:1375–1377.
   PubMed Web of Science ®Google Scholar
• Heikkilä T, Salonen J, Tuura J, et al. Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm. 2007;331(1):133–138.
   PubMed Web of Science ®Google Scholar
• Kresge C, Leonowicz M, Roth W, et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature. 1992;359(6397):710–712.
   Web of Science ®Google Scholar
• Salonen J, Kaukonen AM, Hirvonen J, et al. Mesoporous silicon in drug delivery applications. J Pharm Sci. 2008;97(2):632–653.
   PubMed Web of Science ®Google Scholar
• Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm. 2010;390(2):165–173.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products; 2015 [cited 2015 Sep 14]. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm.
   Google Scholar
• Fu C, Liu T, Li L, et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013;34(10):2565–2575.
   PubMed Web of Science ®Google Scholar
• Hudson SP, Padera RF, Langer R, et al. The biocompatibility of mesoporous silicates. Biomaterials. 2008;29(30):4045–4055.
   PubMed Web of Science ®Google Scholar
• Manzano M, Colilla M, Vallet-Regí M. Drug delivery from ordered mesoporous matrices. Expert Opin Drug Deliv. 2009;6(12):1383–1400.
   PubMed Web of Science ®Google Scholar
• Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev. 2012;64(15):1800–1819.
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Owen SC, et al. Handbook of pharmaceutical excipients. Vol. 6. London: Pharmaceutical press; 2006.
   Google Scholar
• Kim J. Synthesis of MCM-48 single crystals. Chem Commun. 1998;2:259–260.
   Web of Science ®Google Scholar
• Izquierdo-Barba I, Martinez Á, Doadrio AL, et al. Release evaluation of drugs from ordered three-dimensional silica structures. Eur J Pharm Sci. 2005;26(5):365–373.
   PubMed Web of Science ®Google Scholar
• Zhao D, Feng J, Huo Q, et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science. 1998;279(5350):548–552.
   PubMed Web of Science ®Google Scholar
• Inagaki S, Koiwai A, Suzuki N, et al. Syntheses of highly ordered mesoporous materials, FSM-16, derived from Kanemite. Bull Chem Soc Jpn. 1996;69(5):1449–1457.
   Web of Science ®Google Scholar
• Jansen J, Shan Z, Marchese L, et al. A new templating method for three-dimensional mesopore networks. Chem Commun. 2001;8:713–714.
   Web of Science ®Google Scholar
• Takeuchi H, Nagira S, Yamamoto H, et al. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm. 2005;293(1–2):155–164.
   PubMed Web of Science ®Google Scholar
• Kinnari P, Mäkilä E, Heikkilä T, et al. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm. 2011;414(1–2):148–156.
   PubMed Web of Science ®Google Scholar
• Friedrich H, Fussnegger B, Kolter K, et al. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm. 2006;62(2):171–177.
   PubMed Web of Science ®Google Scholar
• Bend Research. Spray-Dried NanoAdsorbate (SDNA) Technology; 2014 [cited 2015 Feb 4]. Available from: http://www.bendresearch.com/drug-delivery-technologies/spray-dried-composite-sdc-technology.
   Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534.
   PubMed Web of Science ®Google Scholar
• Azaïs T, Tourné-Péteilh C, Aussenac F, et al. Solid-state NMR study of ibuprofen confined in MCM-41 material. Chem Mater. 2006;18(26):6382–6390.
   Web of Science ®Google Scholar
• Shen SC, Ng WK, Chia L, et al. Stabilized amorphous state of ibuprofen by co‐spray drying with mesoporous SBA‐15 to enhance dissolution properties. J Pharm Sci. 2010;99(4):1997–2007.
   PubMed Web of Science ®Google Scholar
• Charnay C, Bégu S, Tourné-Péteilh C, et al. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur J Pharm Biophar. 2004;57(3):533–540.
   PubMed Web of Science ®Google Scholar
• Hong S, Shen S, Tan DCT, et al. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods. Drug Deliv. 2015;July 21:1–12.
   Google Scholar
• Sliwinska-Bartkowiak M, Dudziak G, Gras R, et al. Freezing behavior in porous glasses and MCM-41. Colloids Surf A Physicochem Eng Asp. 2001;187:523–529.
   Web of Science ®Google Scholar
• Brás AR, Fonseca IM, Dionísio M, et al. Influence of nanoscale confinement on the molecular mobility of ibuprofen. J Phys Chem C. 2014;118(25):13857–13868.
   Web of Science ®Google Scholar
• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397–404.
   PubMed Web of Science ®Google Scholar
• FUJI SILYSIA CHEMICAL LTD. Sylysia; 2015 [cited 2015 Sep 14]. Available from: http://www.fujisilysia.com/products/sylysia/.
   Google Scholar
• Grace WR, Conn C. Syloid silica excipients for pharmaceutical applications; 2014 [cited 2015 Apr 28]. Available from: https://grace.com/pharma-and-biotech/en-us/Documents/Syloid/B561b_SYLOID_8.5x11VERSION_9-18-14_FINAL.pdf.
   Google Scholar
• Gumaste SG, Pawlak SA, Dalrymple DM, et al. Development of solid SEDDS, IV: effect of adsorbed lipid and surfactant on tableting properties and surface structures of different silicates. Pharm Res. 2013;30(12):3170–3185.
   PubMed Web of Science ®Google Scholar
• Galarneau A, Nader M, Guenneau F, et al. Understanding the stability in water of mesoporous SBA-15 and MCM-41. J Phys Chem C. 2007;111(23):8268–8277.
   Web of Science ®Google Scholar
• Merck Millipore. Merck Millipore Introduces Parteck® SLC, Silica-based Excipient for Enhanced Drug Solubility and Bioavailability. Darmstadt: Merck Millipore Corporation; 2013.
   Google Scholar
• Andersson J, Rosenholm J, Areva S, et al. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro-and mesoporous silica matrices. Chem Mater. 2004;16(21):4160–4167.
   Web of Science ®Google Scholar
• Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv. 2011;8(10):1361–1378.
   PubMed Web of Science ®Google Scholar
• Prestidge CA, Barnes TJ, Lau C-H, et al. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin Drug Deliv. 2007;4(2):101–110.
   Google Scholar
• Ahern RJ, Hanrahan JP, Tobin JM, et al. Comparison of fenofibrate–mesoporous silica drug-loading processes for enhanced drug delivery. Eur J Pharm Sci. 2013;50(3–4):400–409.
   PubMed Web of Science ®Google Scholar

* Informative comparison of different drug loading methods

• Mellaerts R, Jammaer JAG, Van Speybroeck M, et al. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir. 2008;24(16):8651–8659.
   PubMed Web of Science ®Google Scholar

** Interesting article on drug distribution in pores

• Waters LJ, Bedford S, Parkes GMB. Controlled microwave processing applied to the pharmaceutical formulation of ibuprofen. AAPS PharmSciTech. 2011;12(4):1038–1043.
   PubMed Web of Science ®Google Scholar
• Waters LJ, Hussain T, Parkes G, et al. Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation. Eur J Pharm Biopharm. 2013;85(3):936–941.
   PubMed Web of Science ®Google Scholar
• Qu F, Zhu G, Lin H, et al. A controlled release of ibuprofen by systematically tailoring the morphology of mesoporous silica materials. J Solid State Chem. 2006;179(7):2027–2035.
   Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Pagano C, et al. MCM-41 for furosemide dissolution improvement. Microporous Mesoporous Mater. 2012;147(1):343–349.
   Web of Science ®Google Scholar
• Qian KK, Bogner RH. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J Pharm Sci. 2012;101(2): 444–463.
   PubMed Web of Science ®Google Scholar
• ICH. Impurities: guideline for residual solvents Q3C(R5) [Internet]. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2011 Feb. [cited 2014 Oct 20]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf
   Google Scholar
• Hata H, Saeki S, Kimura T, et al. Adsorption of taxol into ordered mesoporous silicas with various pore diameters. Chem Mater. 1999;11(4):1110–1119.
   Web of Science ®Google Scholar
• Heikkilä T, Salonen J, Tuura J, et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv. 2007;14(6):337–347.
   PubMed Web of Science ®Google Scholar
• Lehto V, Riikonen J, Santos H. Drug loading and characterization of porous silicon materials. In: Santos HA, editor. Porous silicon for biomedical applications. Cambridge: Woodhead Publishing Limited; 2014. p. 337.
   Google Scholar
• Mellaerts R, Houthoofd K, Elen K, et al. Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material. Microporous Mesoporous Mater. 2010;130(1):154–161.
   Web of Science ®Google Scholar

**Informative article on stability of mesoporous silica drug formulations

• Van Speybroeck M, Mols R, Mellaerts R, et al. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur J Pharm Biopharm. 2010;75(3):354–365.
   PubMed Web of Science ®Google Scholar

* Interesting article on in vivo drug delivery from mesoporous silica formulations

• Van Speybroeck M, Mellaerts R, Thi TD, et al. Preventing release in the acidic environment of the stomach via occlusion in ordered mesoporous silica enhances the absorption of poorly soluble weakly acidic drugs. J Pharm Sci. 2011;100(11):4864–4876.
   PubMed Web of Science ®Google Scholar
• Kruk M, Jaroniec M, Ko CH, et al. Characterization of the porous structure of SBA-15. Chem Mater. 2000;12(7):1961–1968.
   Web of Science ®Google Scholar
• Vetere A. A short-cut method to predict the solubilities of solids in supercritical carbon dioxide. Fluid Phase Equilib. 1998;148(1–2):83–93.
   Web of Science ®Google Scholar
• Gignone A, Manna L, Ronchetti S, et al. Incorporation of clotrimazole in ordered mesoporous silica by supercritical CO2. Microporous Mesoporous Mater. 2014;200:291–296.
   Web of Science ®Google Scholar
• Ahern RJ, Crean AM, Ryan KB. The influence of supercritical carbon dioxide (SC-CO2) processing conditions on drug loading and physicochemical properties. Int J Pharm. 2012;439(1):92–99.
   PubMed Web of Science ®Google Scholar
• Limnell T, Santos HA, Mäkilä E, et al. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods. J Pharm Sci. 2011;100(8):3294–3306.
   PubMed Web of Science ®Google Scholar

* Informative report on loading methods for scale-up processes

• Bahl D, Hudak J, Bogner RH. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharm Dev Technol. 2008;13(3):255–269.
   PubMed Web of Science ®Google Scholar
• Aerts CA, Verraedt E, Mellaerts R, et al. Tunability of pore diameter and particle size of amorphous microporous silica for diffusive controlled release of drug compounds. J Phys Chem C. 2007;111(36):13404–13409.
   Web of Science ®Google Scholar
• Horcajada P, Ramila A, Perez-Pariente J, et al. Influence of pore size of MCM-41 matrices on drug delivery rate. Microporous Mesoporous Mater. 2004;68(1):105–109.
   Web of Science ®Google Scholar
• Tozuka Y, Wongmekiat A, Kimura K, et al. Effect of pore size of FSM-16 on the entrapment of flurbiprofen in mesoporous structures. Chem Pharm Bull. 2005;53(8):974–977.
   PubMed Web of Science ®Google Scholar
• Ukmar T, Maver U, Planinšek O, et al. Understanding controlled drug release from mesoporous silicates: theory and experiment. J Control Release. 2011;155(3):409–417.
   PubMed Web of Science ®Google Scholar
• Gao L, Sun J, Zhang L, et al. Influence of different structured channels of mesoporous silicate on the controlled ibuprofen delivery. Mater Chem Phys. 2012;135(2–3):786–797.
   Web of Science ®Google Scholar
• Zhu Y-F, Shi J-L, Li Y-S, et al. Hollow mesoporous spheres with cubic pore network as a potential carrier for drug storage and its in vitro release kinetics. J Mater Res. 2005;20(1):54–61.
   Web of Science ®Google Scholar
• Zhang Y, Zhi Z, Jiang T, et al. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release. 2010;145(3):257–263.
   PubMed Web of Science ®Google Scholar
• Rengarajan G, Enke D, Steinhart M, et al. Stabilization of the amorphous state of pharmaceuticals in nanopores. J Mater Chem. 2008;18(22):2537–2539.
   Web of Science ®Google Scholar
• Jia LJ, Shen JY, Li ZY, et al. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs. Int J Pharm. 2012;439(1–2):81–91.
   PubMed Web of Science ®Google Scholar
• Shen S-C, Ng WK, Chia L, et al. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. Int J Pharm. 2011;410(1–2):188–195.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wang J, Zhi Z, et al. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J Colloid Interface Sci. 2011;363(1): 410–417.
   PubMed Web of Science ®Google Scholar
• Xu W, Riikonen J, Lehto V-P. Mesoporous systems for poorly soluble drugs. Int J Pharm. 2013;453(1):181–197.
   PubMed Web of Science ®Google Scholar

** Comprehensive review of the utilization of inorganic mesoporous materials in formulations of poorly water-soluble drugs to enhance their dissolution

• Miura H, Kanebako M, Shirai H, et al. Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state 13C NMR spectroscopy. Int J Pharm. 2011;410(1–2):61–67.
   PubMed Web of Science ®Google Scholar
• Van Speybroeck M, Mellaerts R, Mols R, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. 2010;41(5): 623–630.
   PubMed Web of Science ®Google Scholar
• Qi L, Ma J, Cheng H, et al. Micrometer-sized mesoporous silica spheres grown under static conditions. Chem Mater. 1998;10(6):1623–1626.
   Web of Science ®Google Scholar
• Slowing II, Vivero-Escoto JL, Wu C-W, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278–1288.
   PubMed Web of Science ®Google Scholar
• Qu F, Zhu G, Huang S, et al. Controlled release of captopril by regulating the pore size and morphology of ordered mesoporous silica. Microporous Mesoporous Mater. 2006;92(1–3):1–9.
   Web of Science ®Google Scholar
• Manzano M, Aina V, Areán CO, et al. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization. Chem Eng J. 2008;137(1):30–37.
   Web of Science ®Google Scholar
• Hu J, Rogers TL, Brown J, et al. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. Pharm Res. 2002;19(9):1278–1284.
   PubMed Web of Science ®Google Scholar
• Kumar D, Sailaja Chirravuri SV, Shastri NR. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac. Int J Pharm. 2014;461(1–2):459–468.
   PubMed Web of Science ®Google Scholar
• Song SW, Hidajat K, Kawi S. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix−drug interactions. Langmuir. 2005;21(21):9568–9575.
   PubMed Web of Science ®Google Scholar
• Balas F, Manzano M, Horcajada P, et al. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc. 2006;128(25):8116–8117.
   PubMed Web of Science ®Google Scholar
• Doadrio JC, Sousa EM, Izquierdo-Barba I, et al. Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern. J Mater Chem. 2006;16(5):462–466.
   Web of Science ®Google Scholar
• Qu F, Zhu G, Huang S, et al. Effective controlled release of captopril by silylation of mesoporous MCM-41. Chem Phys Chem. 2006;7(2):400–406.
   Google Scholar
• Tang Q, Yao X, Dong W, et al. Studies on a new carrier of trimethylsilyl-modified mesoporous material for controlled drug delivery. J Control Release. 2006;114(1):41–46.
   PubMed Web of Science ®Google Scholar
• Moritz M, Łaniecki M. SBA-15 mesoporous material modified with APTES as the carrier for 2-(3-benzoylphenyl) propionic acid. Appl Surf Sci. 2012;258(19):7523–7529.
   Web of Science ®Google Scholar
• Guo Z, Liu X-M, Ma L, et al. Effects of particle morphology, pore size and surface coating of mesoporous silica on naproxen dissolution rate enhancement. Colloids Surf B Biointerfaces. 2013;101:228–235.
   PubMed Web of Science ®Google Scholar
• Nastase S, Bajenaru L, Matei C, et al. Ordered mesoporous silica and aluminosilicate-type matrix for amikacin delivery systems. Microporous Mesoporous Mater. 2013;182:32–39.
   Web of Science ®Google Scholar
• Carmona D, Balas F, Santamaria J. Pore ordering and surface properties of FDU-12 and SBA-15 mesoporous materials and their relation to drug loading and release in aqueous environments. Mater Res Bull. 2014;59:311–322.
   Web of Science ®Google Scholar
• Jambhrunkar S, Qu Z, Popat A, et al. Modulating in vitro release and solubility of griseofulvin using functionalized mesoporous silica nanoparticles. J Colloid Interface Sci. 2014;434:218–225.
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Popova M, Szegedi A, et al. Functionalized mesoporous silica nanoparticles for oral delivery of budesonide. J Solid State Chem. 2014;211:154–161.
   Web of Science ®Google Scholar
• Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12.
   PubMed Web of Science ®Google Scholar
• Morris KR, Griesser UJ, Eckhardt CJ, et al. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev. 2001;48(1):91–114.
   PubMed Web of Science ®Google Scholar
• Limnell T, Riikonen J, Salonen J, et al. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. Int J Pharm. 2007;343(1–2):141–147.
   PubMed Web of Science ®Google Scholar
• Limnell T, Heikkilä T, Santos HA, et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int J Pharm. 2011;416(1):242–251.
   PubMed Web of Science ®Google Scholar
• Qian K, Wurster D, Bogner R. Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 3: effect of moisture. Pharm Res. 2012;29(10):2698–2709.
   PubMed Web of Science ®Google Scholar
• Hailu SA, Bogner RH. Complex effects of drug/silicate ratio, solid-state equivalent pH, and moisture on chemical stability of amorphous quinapril hydrochloride coground with silicates. J Pharm Sci. 2011;100(4):1503–1515.
   PubMed Web of Science ®Google Scholar
• Pan X, Julian T, Augsburger L. Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethicin. Drug Dev Ind Pharm. 2008;34(2):221–231.
   PubMed Web of Science ®Google Scholar
• Bahl D, Bogner R. Amorphization of indomethacin by co-grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm Res. 2006;23(10):2317–2325.
   PubMed Web of Science ®Google Scholar
• Mellaerts R, Roeffaers MBJ, Houthoofd K, et al. Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material. Phys Chem Chem Phys. 2011;13(7): 2706–2713.
   PubMed Web of Science ®Google Scholar
• Shalaev EY, Zografi G. How does residual water affect the solid‐state degradation of drugs in the amorphous state? J Pharm Sci. 1996;85(11):1137–1141.
   PubMed Web of Science ®Google Scholar
• Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001;48(1):115–136.
   PubMed Web of Science ®Google Scholar
• Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013;453(1):12–24.
   PubMed Web of Science ®Google Scholar
• Vialpando M, Martens JA, Van den Mooter G. Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs. Ther Deliv. 2011;2(8):1079–1091.
   PubMedGoogle Scholar
• Wang S. Ordered mesoporous materials for drug delivery. Microporous Mesoporous Mater. 2009;117(1):1–9.
   Web of Science ®Google Scholar
• Xue JM, Shi M. PLGA/mesoporous silica hybrid structure for controlled drug release. J Control Release. 2004;98(2):209–217.
   PubMed Web of Science ®Google Scholar
• Bui TX, Choi H. Adsorptive removal of selected pharmaceuticals by mesoporous silica SBA-15. J Hazard Mater. 2009;168(2):602–608.
   PubMed Web of Science ®Google Scholar
• Turku I, Sainio T, Paatero E. Thermodynamics of tetracycline adsorption on silica. Environ Chem Lett. 2007;5(4):225–228.
   Web of Science ®Google Scholar
• Ahern RJ. Application of mesoporous silica for the oral delivery of poorly water soluble drugs, in school of pharmacy. Ireland: University College Cork; 2013.
   Google Scholar
• Atkin R, Craig VSJ, Wanless EJ, et al. Mechanism of cationic surfactant adsorption at the solid–aqueous interface. Adv Colloid Interface Sci. 2003;103(3):219–304.
   PubMed Web of Science ®Google Scholar
• Guzman HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96(10):2686–2702.
   PubMed Web of Science ®Google Scholar
• Vandecruys R, Peeters J, Verreck G, et al. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm. 2007;342(1):168–175.
   PubMed Web of Science ®Google Scholar
• Mellaerts R, Mols R, Kayaert P, et al. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int J Pharm. 2008;357(1–2):169–179.
   PubMed Web of Science ®Google Scholar
• Mellaerts R, Mols R, Jammaer JAG, et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008;69(1):223–230.
   PubMed Web of Science ®Google Scholar
• Vialpando M, Aerts A, Persoons J, et al. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release. J Pharm Sci. 2011;100(8):3411–3420.
   PubMed Web of Science ®Google Scholar
• Kiekens F, Eelen S, Verheyden L, et al. Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J Pharm Sci. 2012;101(3):1136–1144.
   PubMed Web of Science ®Google Scholar
• Peng T, Zhu C, Huang Y, et al. Improvement of the stability of doxycycline hydrochloride pellet-containing tablets through a novel granulation technique and proper excipients. Powder Technol. 2015;270, (Part A): 221–229.
   Web of Science ®Google Scholar
• Vialpando M, Backhuijs F, Martens JA, et al. Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen. Eur J Pharm Biopharm. 2012;81(1): 190–198.
   PubMed Web of Science ®Google Scholar

* Informative report on manufacturing challenges

• Cassiers K, Linssen T, Mathieu M, et al. A detailed study of thermal, hydrothermal, and mechanical stabilities of a wide range of surfactant assembled mesoporous silicas. Chem Mater. 2002;14(5):2317–2324.
   Web of Science ®Google Scholar
• Choudhari Y, Reddy U, Monsuur F, et al. Comparative evaluation of porous silica based carriers for lipids and liquid drug formulations. Mesoporous Biomater. 2014;1:1.
   Google Scholar
• Wang ZH, Chen B, Quan GL, et al. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica. Int J Nanomedicine. 2012;7:5807–5818.
   PubMed Web of Science ®Google Scholar
• Formac Pharmaceuticals. Formac pharmaceuticals; pipeline; 2015 [cited 2015 Mar 25]. Available from: http://www.formacpharma.com/index.php?page=pipeline&sub=6.
   Google Scholar
• Glantreo Ltd. Glantreo; innovative nanomaterials for drug delivery; 2015 [cited 2015 Mar 25]. Available from: http://www.glantreo.com/application-areas/pharmaceuticals/.
   Google Scholar
• Nanologica AB. NLAB silica – next generation platform technology in drug delivery; 2014 [cited 2015 Apr 29]; Available from: http://www.nanologica.com/drug-delivery.
   Google Scholar